Latest News

Monday, August 03, 2015 | Miscellaneous, Heidelberg Engineering

Heidelberg Engineering to Relocate US Headquarters to the East Coast

Heidelberg Engineering is relocating its US headquarters from Carlsbad, California to Franklin, Massachusetts, according to a company news release. The new location on the east coast will inte…

Read the full story

Monday, August 03, 2015 | FDA Approval/Clearance, Bausch+Lomb

Bausch + Lomb's Victus Femtosecond Laser Platform Receives 510(k) Clearance from FDA for Enhanced Patient Interface Kit

Bausch + Lomb announced today its Victus Femtosecond Laser Platform has received 510(k) clearance from the FDA for an enhanced patient interface kit, according to a company news release. The interface…

Read the full story

Monday, August 03, 2015 | Medical Studies

Human Lacrimal Glands Visualized With OCT

Human lacrimal glands can be successfully imaged using optical coherence tomography (OCT), a new study shows. The images did not provide a way to distinguish healthy eyes from those with dry eye syndr…

Read the full story

Monday, August 03, 2015 | Acquisitions/Mergers, Shire

Shire Acquires Foresight Biotherapeutics for $300 Million

Shire announced that it has acquired New York-based, privately held Foresight Biotherapeutics for $300 million. With the acquisition, Shire acquires the global rights to FST-100 (topical ophthalmic dr…

Read the full story

Monday, August 03, 2015 | Medical Studies

Patients With Psoriasis Should be Examined for Uveitis

A newly identified bidirectional association between psoriatic disease and uveitis has led researchers to suggest that patients with psoriasis and psoriatic arthritis should be closely evaluated for e…

Read the full story

Friday, July 31, 2015 | Medical Studies

Human Lacrimal Glands Visualized With OCT

Human lacrimal glands can be successfully imaged using optical coherence tomography (OCT), a new study shows. The images did not provide a way to distinguish healthy eyes from those with dry eye syndr…

Read the full story

Friday, July 31, 2015 | Glaucoma, Product Releases, Glaukos Corporation

Glaukos Receives Regulatory Approval in Australia for iStent Inject

Glaukos announced regulatory approval from the Australian Therapeutic Goods Administration (TGA) for its iStent inject Trabecular Micro-Bypass Stent, according to a company news release. With TGA appr…

Read the full story

Friday, July 31, 2015 | Medical Studies

Patients With Psoriasis Should be Examined for Uveitis

A newly identified bidirectional association between psoriatic disease and uveitis has led researchers to suggest that patients with psoriasis and psoriatic arthritis should be closely evaluated for e…

Read the full story

Friday, July 31, 2015 | Management/Leadership

Alcon Announces Leadership Change for North American Region

Alcon has appointed Sergio Duplan as region president, Alcon North America. He succeeds Robert Warner, who assumes a new Alcon executive committee role as global franchise head, Alcon Vision Care, acc…

Read the full story

Thursday, July 30, 2015 | Acquisitions/Mergers

Brazos Private Equity Partners To Sell Vision Source To Essilor

Brazos Private Equity Partners, a Dallas-based private investment firm, announced that it has agreed to sell its portfolio company, Vision Source, to Essilor of America, a subsidiary of Paris-based Es…

Read the full story

Thursday, July 30, 2015 | Medical Studies

Chemosurgery Appears No Less Safe Than Enucleation in Advanced Eye Cancer

Ophthalmic artery chemosurgery (OAC) for advanced-stage retinoblastoma appears at least as safe as enucleation, according to New York-based researchers. "This paper reassures clinicians worldwide…

Read the full story

Thursday, July 30, 2015 | Earnings & Financials

Inotek Pharmaceuticals Announces Conversion of $21 Million Principal Amount of 5.0% Convertible Senior Notes Due 2020

Inotek Pharmaceuticals announced that $20,970,000 of its 5.0% Convertible Senior Notes due 2020 (the “2020 Notes”) maturing February 15, 2020 have been converted into shares of common stoc…

Read the full story

Thursday, July 30, 2015 | Clinical Trials, Bayer

Phase 3 Trials for Uveal Melanoma Therapy, Beh├žet Disease Uveitis Fail to Reach Primary Endpoints

Phase 3 clinical trials investigating potential therapies for uveal melanoma and for Behçet disease uveitis failed to reach their primary endpoints, according to information from the two drugs&…

Read the full story

Wednesday, July 29, 2015 | Product Releases

Adaptica to Launch VisionFit Wearable Adaptive Refractor at ESCRS 2015 in Barcelona

Adaptica will launch its VisionFit Wearable Adaptive Refractor at the upcoming European Society of Cataract & Refractive Surgeons (ESCRS) meeting taking place at the Fira Gran Via, Barcelona…

Read the full story

Wednesday, July 29, 2015 | Health Care

By 2024, Health Spending Will be Nearly a Fifth of the Economy

A sharp rise in prescription drug spending, driven largely by a new generation of expensive hepatitis C drugs, helped push the nation's health-care expenditures to $3.1 trillion in 2014 -- the big…

Read the full story
Load More
 Stock Price  Change 
 Actavis $298.98  0.00% 
 Aerie Pharmaceuticals, Inc. $18.14  0.00% 
 Akorn, Inc. $46.16  0.11% 
 Alimera Sciences, Inc. $4.77  -1.04% 
 Avalanche Biotechnologies $15.39  4.55% 
 Bayer $148.13  0.25% 
 Can-Fite Biopharma $1.91  -2.55% 
 Carl Zeiss Meditec $26.21  2.26% 
 Cooper Companies, Inc. $177.15  0.08% 
 Eleven Biotherapeutics $2.71  -2.17% 
 Escalon Medical Corp. $1.39  -1.42% 
 Essilor International $128.25  0.00% 
 Imprimis Pharmaceuticals, Inc. $7.84  -0.38% 
 InSite Vision, Inc. $0.18  0.00% 
 IRIDEX Corporation $7.00  -2.23% 
 Johnson & Johnson $100.02  -0.19% 
 Luxottica Group, S.p.A. $72.68  0.64% 
 Merck & Company, Inc. $59.05  0.15% 
 NicOx $1.82  0.17% 
 NovaBay Pharmaceuticals, Inc. $0.59  1.67% 
 Novartis AG Common Stock $104.36  0.59% 
 Ocular Therapeutix $22.05  -4.50% 
 Ophthotech Corporation $70.34  3.91% 
 QLT $3.78  0.27% 
 Quantel $3.05  0.66% 
 Regeneron $554.27  0.11% 
 Roche $35.95  -0.44% 
 Second Sight Medical Products $14.08  -0.21% 
 STAAR Surgical Company $8.19  -6.61% 
 TearLab Corporation $2.79  12.05% 
 Thrombogenics $5.39  0.00% 
 Topcon Corporation $18.45  -14.39% 
 Valeant Pharmaceuticals $257.21  -0.12% 
 Xoma $0.77  5.89%